D models of uveal melanoma are transforming cancer research, enabling personalized treatments and better drug testing for ...

After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

Detailed price information for Delcath Systems Inc (DCTH-Q) from The Globe and Mail including charting and trades.

Uveal melanoma, which develops from cells in the middle layer of the eye, known as the uvea, is thought to affect between 500 and 600 people in the UK each year. Tebentafusp, sold under the brand ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Immunocore Holdings (IMCR – Research Report), retaining the price target ...

NICE has recommended tebentafusp as an option for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it ...

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There are different types of eye cancer. Chemotherapy does not usually work well for melanoma of the eyeball (uveal melanoma). Your specialist might suggest it if your melanoma has spread and if there ...